抗独特型诱导疗法：抗CA125抗体（Ab3）介导用Ovarex单克隆抗体B43.13（Ab1）治疗的患者体内的肿瘤杀伤。
Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).
作者信息
Schultes B C, Baum R P, Niesen A, Noujaim A A, Madiyalakan R
机构信息
AltaRex Corp., Edmonton, Alberta, Canada.
出版信息
Cancer Immunol Immunother. 1998 Jun;46(4):201-12. doi: 10.1007/s002620050479.
Intravenous injection of the murine monoclonal anti-CA125 antibody B43.13 (Ovarex: Ab1) into ovarian cancer patients led to the induction of an idiotypic network. Of the 75 patients who received one to ten injections of a 2-mg dose of the antibody, 48 developed anti-(mAb B43.13) antibodies (Ab2); 18 of these patients also had elevated levels of anti-[anti-(mAb B43.13)] antibodies (Ab3; = anti-CA125 antibodies) compared to pre-injection values. Characterization of these antibodies revealed that the binding to CA125 could be inhibited by mAb B43.13 in most samples. Human anti-CA125 antibodies or Ab3 purified from patient serum samples specifically recognized human ovarian tumor cells and tissues expressing CA125. In addition, these anti-CA125 antibodies were able to conduct Fc-mediated tumor cell killing (antibody-dependent cell-mediated cytotoxicity). This raises the possibility of using an Ab1 for anti-idiotype induction immunotherapy of cancer.
向卵巢癌患者静脉注射鼠单克隆抗CA125抗体B43.13（Ovarex：Ab1）可诱导独特型网络的形成。在接受1至10次2毫克剂量抗体注射的75名患者中，48人产生了抗（单克隆抗体B43.13）抗体（Ab2）；与注射前相比，其中18名患者的抗[抗（单克隆抗体B43.13）]抗体（Ab3；即抗CA125抗体）水平也有所升高。对这些抗体的特性分析表明，在大多数样本中，单克隆抗体B43.13可抑制其与CA125的结合。从患者血清样本中纯化的人抗CA125抗体或Ab3可特异性识别表达CA125的人卵巢肿瘤细胞和组织。此外，这些抗CA125抗体能够介导Fc介导的肿瘤细胞杀伤（抗体依赖性细胞介导的细胞毒性）。这增加了使用Ab1进行癌症抗独特型诱导免疫治疗的可能性。
Zotero 插件